NurExone Biologic Past Earnings Performance

Past criteria checks 0/6

NurExone Biologic's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.

Key information

-9.0%

Earnings growth rate

13.9%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth raten/a
Return on equity-160.8%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

Jun 12
We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

Revenue & Expenses Breakdown

How NurExone Biologic makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:NRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-430
31 Mar 240-420
31 Dec 230-420
30 Sep 230-420
30 Jun 230-420
31 Mar 230-730
31 Dec 220-840
30 Sep 220-840
30 Jun 220-740
31 Mar 220-430

Quality Earnings: NRX is currently unprofitable.

Growing Profit Margin: NRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).


Return on Equity

High ROE: NRX has a negative Return on Equity (-160.82%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies